500mg Fulvestrant Versus Everolimus Plus Exemestane in MBC Patients Refractory to Previous AI

Fulvestrant Versus Everolimus Plus Exemestane for Patients With Metastatic Breast Cancer Resistant to Aromatase Inhibitors: the Clinical Experience From Real -World

500mg Fulvestrant versus Everolimus plus Exemestane in MBC patients refractory to previous AI

Fulvestrant versus Everolimus plus Exemestane for patients with Metastatic Breast Cancer resistant to Aromatase Inhibitors: the clinical experience from real -world

Inclusion Criteria:

1. Patients diagnosed with ER/PR+，HER2- Metastatic Breast Cancer
2. Patients who were refractory to previous Aromatase Inhibitors
3. Patients treated with Fulvestrant or Everolimus plus Exemestane in any line in metastatic setting in Fudan University Shanghai Cancer Center，starting from 2013.06.01-2016.06.01
4. Available medical history

Exclusion Criteria:

1.Incomplete medical history